Metraipolis › archive › dc_b8cdfd4472d8

Low-dose methotrexate adverse reaction risk in renal impairment: pharmacovigilance and physiological pharmacokinetic model assessment — Europe PMC PMID:41282623

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41282623
DOI
10.3389/fphar.2025.1703557
License (as archived)
solo-consultazione
Archived
2026-11-08T18:33:18.052Z
SHA-256 of the archived text
c48016372efcd3f9d87a0ce284a461bd8069d7c7f9ddb15a1631b6736560362d
Stable URL of this page
https://metraipolis.com/documento/dc_b8cdfd4472d8

How to cite

Low-dose methotrexate adverse reaction risk in renal impairment: pharmacovigilance and physiological pharmacokinetic model assessment — Europe PMC PMID:41282623 — Europe PMC (en), https://europepmc.org/article/MED/41282623 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_b8cdfd4472d8 (Metraipolis archive dc_b8cdfd4472d8, sha256 c48016372efcd3f9d87a0ce284a461bd8069d7c7f9ddb15a1631b6736560362d)
BibTeX
@misc{dcb8cdfd4472d8,
  title = {Low-dose methotrexate adverse reaction risk in renal impairment: pharmacovigilance and physiological pharmacokinetic model assessment — Europe PMC PMID:41282623},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41282623},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_b8cdfd4472d8; sha256 c48016372efcd3f9d87a0ce284a461bd8069d7c7f9ddb15a1631b6736560362d},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41282623. Agents can read the archived copy with the MCP tool read_document.